A citation-based method for searching scientific literature

Judith Müller, Oscar Krijgsman, Jennifer Tsoi, Lidia Robert, Willy Hugo, Chunying Song, Xiangju Kong, Patricia A Possik, Paulien D M Cornelissen-Steijger, Marnix H Geukes Foppen, Kristel Kemper, Colin R Goding, Ultan McDermott, Christian Blank, John Haanen, Thomas G Graeber, Antoni Ribas, Roger S Lo, Daniel S Peeper. Nat Commun 2014
Times Cited: 359







List of co-cited articles
1254 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
David J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, Jong Wook Kim, Zachary A Cooper, Adriano Piris, Dennie T Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq,[...]. Cancer Discov 2014
326
46

Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, Sara Aibar, Julia Femel, Michael Dewaele, Panagiotis Karras, Daniel Brown, Young Hwan Chang, Maria Debiec-Rychter,[...]. Cell 2018
249
38

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Itay Tirosh, Benjamin Izar, Sanjay M Prakadan, Marc H Wadsworth, Daniel Treacy, John J Trombetta, Asaf Rotem, Christopher Rodman, Christine Lian, George Murphy,[...]. Science 2016
37

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.
Jennifer Tsoi, Lidia Robert, Kim Paraiso, Carlos Galvan, Katherine M Sheu, Johnson Lay, Deborah J L Wong, Mohammad Atefi, Roksana Shirazi, Xiaoyan Wang,[...]. Cancer Cell 2018
278
37


In vivo switching of human melanoma cells between proliferative and invasive states.
Keith S Hoek, Ossia M Eichhoff, Natalie C Schlegel, Udo Döbbeling, Nikita Kobert, Leo Schaerer, Silvio Hemmi, Reinhard Dummer. Cancer Res 2008
448
30

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities.
Florian Rambow, Jean-Christophe Marine, Colin R Goding. Genes Dev 2019
96
29

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Willy Hugo, Hubing Shi, Lu Sun, Marco Piva, Chunying Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B Dahlman, Douglas B Johnson,[...]. Cell 2015
371
27

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Annelien Verfaillie, Hana Imrichova, Zeynep Kalender Atak, Michael Dewaele, Florian Rambow, Gert Hulselmans, Valerie Christiaens, Dmitry Svetlichnyy, Flavie Luciani, Laura Van den Mooter,[...]. Nat Commun 2015
228
27

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
26

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Julia Boshuizen, Louise A Koopman, Oscar Krijgsman, Aida Shahrabi, Elke Gresnigt- van den Heuvel, Maarten A Ligtenberg, David W Vredevoogd, Kristel Kemper, Thomas Kuilman, Ji-Ying Song,[...]. Nat Med 2018
114
25

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Keith S Hoek, Natalie C Schlegel, Patricia Brafford, Antje Sucker, Selma Ugurel, Rajiv Kumar, Barbara L Weber, Katherine L Nathanson, David J Phillips, Meenhard Herlyn,[...]. Pigment Cell Res 2006
365
25

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Chong Sun, Liqin Wang, Sidong Huang, Guus J J E Heynen, Anirudh Prahallad, Caroline Robert, John Haanen, Christian Blank, Jelle Wesseling, Stefan M Willems,[...]. Nature 2014
529
25

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar,[...]. Nature 2010
22

Phenotype plasticity as enabler of melanoma progression and therapy resistance.
Imanol Arozarena, Claudia Wellbrock. Nat Rev Cancer 2019
130
21

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Paola Falletta, Luis Sanchez-Del-Campo, Jagat Chauhan, Maike Effern, Amy Kenyon, Christopher J Kershaw, Robert Siddaway, Richard Lisle, Rasmus Freter, Matthew J Daniels,[...]. Genes Dev 2017
137
20

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Sydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, Eduardo A Torre, Benjamin Emert, Clemens Krepler, Marilda Beqiri, Katrin Sproesser, Patricia A Brafford, Min Xiao,[...]. Nature 2017
484
19

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Jennifer Landsberg, Judith Kohlmeyer, Marcel Renn, Tobias Bald, Meri Rogava, Mira Cron, Martina Fatho, Volker Lennerz, Thomas Wölfel, Michael Hölzel,[...]. Nature 2012
363
19

Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma.
Jasper Wouters, Zeynep Kalender-Atak, Liesbeth Minnoye, Katina I Spanier, Maxime De Waegeneer, Carmen Bravo González-Blas, David Mauduit, Kristofer Davie, Gert Hulselmans, Ahmad Najem,[...]. Nat Cell Biol 2020
47
40

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
Cory M Johannessen, Laura A Johnson, Federica Piccioni, Aisha Townes, Dennie T Frederick, Melanie K Donahue, Rajiv Narayan, Keith T Flaherty, Jennifer A Wargo, David E Root,[...]. Nature 2013
326
18

Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
Suzanne Carreira, Jane Goodall, Laurence Denat, Mercedes Rodriguez, Paolo Nuciforo, Keith S Hoek, Alessandro Testori, Lionel Larue, Colin R Goding. Genes Dev 2006
403
17

Cancer stem cells versus phenotype-switching in melanoma.
Keith S Hoek, Colin R Goding. Pigment Cell Melanoma Res 2010
324
17

MITF-the first 25 years.
Colin R Goding, Heinz Arnheiter. Genes Dev 2019
122
17

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, Daniel J Treacy, Cory M Johannessen, Eva M Goetz, Chelsea S Place, Amaro Taylor-Weiner, Steven Whittaker, Gregory V Kryukov,[...]. Cancer Discov 2014
620
16

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.
Stefanie Riesenberg, Angela Groetchen, Robert Siddaway, Tobias Bald, Julia Reinhardt, Denise Smorra, Judith Kohlmeyer, Marcel Renn, Bengt Phung, Pia Aymans,[...]. Nat Commun 2015
118
16

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
15

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
473
15

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Marialuisa Sensi, Mara Catani, Giancarlo Castellano, Gabriella Nicolini, Federica Alciato, Gabrina Tragni, Giuseppina De Santis, Ilaria Bersani, Giancarlo Avanzi, Antonella Tomassetti,[...]. J Invest Dermatol 2011
97
15

MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma.
Marie Ennen, Céline Keime, Giovanni Gambi, Alice Kieny, Sebastien Coassolo, Christelle Thibault-Carpentier, Fanny Margerin-Schaller, Guillaume Davidson, Constance Vagne, Dan Lipsker,[...]. Clin Cancer Res 2017
37
40

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
15

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B Johnson, Kimberly B Dahlman,[...]. Cancer Discov 2014
674
14

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Michael P Smith, Holly Brunton, Emily J Rowling, Jennifer Ferguson, Imanol Arozarena, Zsofia Miskolczi, Jessica L Lee, Maria R Girotti, Richard Marais, Mitchell P Levesque,[...]. Cancer Cell 2016
140
14

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.
Julie Caramel, Eftychios Papadogeorgakis, Louise Hill, Gareth J Browne, Geoffrey Richard, Anne Wierinckx, Gerald Saldanha, Joy Osborne, Peter Hutchinson, Gina Tse,[...]. Cancer Cell 2013
330
14

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Gatien Moriceau, Willy Hugo, Aayoung Hong, Hubing Shi, Xiangju Kong, Clarissa C Yu, Richard C Koya, Ahmed A Samatar, Negar Khanlou, Jonathan Braun,[...]. Cancer Cell 2015
225
13

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Ravid Straussman, Teppei Morikawa, Kevin Shee, Michal Barzily-Rokni, Zhi Rong Qian, Jinyan Du, Ashli Davis, Margaret M Mongare, Joshua Gould, Dennie T Frederick,[...]. Nature 2012
13

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
Alexander Roesch, Mizuho Fukunaga-Kalabis, Elizabeth C Schmidt, Susan E Zabierowski, Patricia A Brafford, Adina Vultur, Devraj Basu, Phyllis Gimotty, Thomas Vogt, Meenhard Herlyn. Cell 2010
812
13

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.
Arnav Mehta, Yeon Joo Kim, Lidia Robert, Jennifer Tsoi, Begoña Comin-Anduix, Beata Berent-Maoz, Alistair J Cochran, James S Economou, Paul C Tumeh, Cristina Puig-Saus,[...]. Cancer Discov 2018
77
16

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Yapeng Su, Wei Wei, Lidia Robert, Min Xue, Jennifer Tsoi, Angel Garcia-Diaz, Blanca Homet Moreno, Jungwoo Kim, Rachel H Ng, Jihoon W Lee,[...]. Proc Natl Acad Sci U S A 2017
109
13

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
13

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Levi A Garraway, Hans R Widlund, Mark A Rubin, Gad Getz, Aaron J Berger, Sridhar Ramaswamy, Rameen Beroukhim, Danny A Milner, Scott R Granter, Jinyan Du,[...]. Nature 2005
13

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Alexander Roesch, Adina Vultur, Ivan Bogeski, Huan Wang, Katharina M Zimmermann, David Speicher, Christina Körbel, Matthias W Laschke, Phyllis A Gimotty, Stephan E Philipp,[...]. Cancer Cell 2013
430
12

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
Y Cheli, S Giuliano, T Botton, S Rocchi, V Hofman, P Hofman, P Bahadoran, C Bertolotto, R Ballotti. Oncogene 2011
157
12

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Livnat Jerby-Arnon, Parin Shah, Michael S Cuoco, Christopher Rodman, Mei-Ju Su, Johannes C Melms, Rachel Leeson, Abhay Kanodia, Shaolin Mei, Jia-Ren Lin,[...]. Cell 2018
447
12

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.
Y Cheli, S Giuliano, N Fenouille, M Allegra, V Hofman, P Hofman, P Bahadoran, J-P Lacour, S Tartare-Deckert, C Bertolotto,[...]. Oncogene 2012
129
11

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Rizwan Haq, Jonathan Shoag, Pedro Andreu-Perez, Satoru Yokoyama, Hannah Edelman, Glenn C Rowe, Dennie T Frederick, Aeron D Hurley, Abhinav Nellore, Andrew L Kung,[...]. Cancer Cell 2013
551
11

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Georgina V Long, Carina Fung, Alexander M Menzies, Gulietta M Pupo, Matteo S Carlino, Jessica Hyman, Hamideh Shahheydari, Varsha Tembe, John F Thompson, Robyn P Saw,[...]. Nat Commun 2014
224
11

Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.
Sophie Pinner, Peter Jordan, Kirsty Sharrock, Laura Bazley, Lucy Collinson, Richard Marais, Elise Bonvin, Colin Goding, Erik Sahai. Cancer Res 2009
151
11

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, Bastian Schilling, Sachet A Shukla, Christian Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H Geukes Foppen, Simone M Goldinger,[...]. Science 2015
11

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Mohammad Fallahi-Sichani, Verena Becker, Benjamin Izar, Gregory J Baker, Jia-Ren Lin, Sarah A Boswell, Parin Shah, Asaf Rotem, Levi A Garraway, Peter K Sorger. Mol Syst Biol 2017
124
11

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley Lomeli, Jin Qian, Clarissa C Yu,[...]. Cancer Discov 2017
87
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.